Medsamic

Tranexamic Acid, the active ingredient in Medsamic, is an antifibrinolytic presented as an intravenous solution for use in controlling bleeding. It is employed to treat bleeding associated with hemophilia, manage heavy menstrual bleeding (menorrhagia), and prevent excessive bleeding during and after surgical procedures.

GNH USA supplies Medsamic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions. We adhere to stringent quality standards to support patient safety and clinical outcomes.

Tranexamic Acid is an antifibrinolytic used to reduce bleeding in several clinical settings.

Hemophilia: reduces the frequency and severity of bleeding episodes in patients with hemophilia. Menorrhagia: decreases menstrual blood loss and improves quality of life for women with heavy periods. Surgical procedures: helps prevent intra‑operative and post‑operative bleeding in patients undergoing various surgeries.

Tranexamic Acid may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Vomiting - Headache - Dizziness - Injection site pain

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Seizures - Visual disturbances (blurred vision, retinal changes) - Severe allergic reactions (anaphylaxis, angioedema)

When using Tranexamic Acid, clinicians should consider several precautionary measures to ensure safe administration.

Renal impairment: adjust dose or avoid use in severe renal dysfunction. History of thromboembolism: avoid or use with caution due to clot risk. Concomitant anticoagulants: monitor coagulation parameters closely. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Pediatric use: safety and efficacy not established; use under specialist supervision. Store at ambient temperature: keep in original container, protect from moisture and light.

Tranexamic Acid can interact with other medicines, influencing clotting or bleeding risk.

Major Interactions (Avoid): - Concurrent use with thrombolytic agents (e.g., alteplase): may reduce therapeutic effect of thrombolysis. - Direct oral anticoagulants (e.g., rivaroxaban, apixaban): increased risk of thrombosis. - Procoagulant factor concentrates (e.g., activated factor VII): heightened clot formation risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding risk if not adequately controlled. - Antiplatelet agents (e.g., aspirin, clopidogrel): may diminish antiplatelet effect. - Diuretics: potential for altered plasma concentration; monitor renal function. - Hormonal contraceptives containing estrogen: possible increased thrombotic risk.